GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prescient Therapeutics Ltd (ASX:PTX) » Definitions » Common Stock

Prescient Therapeutics (ASX:PTX) Common Stock : A$93.27 Mil (As of Dec. 2023)


View and export this data going back to 1986. Start your Free Trial

What is Prescient Therapeutics Common Stock?

Prescient Therapeutics's quarterly common stock increased from Dec. 2022 (A$87.95 Mil) to Jun. 2023 (A$93.25 Mil) and increased from Jun. 2023 (A$93.25 Mil) to Dec. 2023 (A$93.27 Mil).

Prescient Therapeutics's annual common stock increased from Jun. 2022 (A$77.26 Mil) to Jun. 2023 (A$93.25 Mil) and increased from Jun. 2023 (A$93.25 Mil) to Jun. 2024 (A$93.27 Mil).


Prescient Therapeutics Common Stock Historical Data

The historical data trend for Prescient Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prescient Therapeutics Common Stock Chart

Prescient Therapeutics Annual Data
Trend Jun14 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 63.93 76.67 77.26 93.25 93.27

Prescient Therapeutics Semi-Annual Data
Jun14 Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 77.26 87.95 93.25 93.27 93.27

Prescient Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Prescient Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
Level 4, 100 Albert Road, South Melbourne, Melbourne, VIC, AUS, 3205
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.

Prescient Therapeutics Headlines

No Headlines